MDACC Study No:2007-0199 ( NCT No: NCT00946270)
Title:A phase II, prospective, open label study (PO-MMM-PI-0011) to determine the safety and efficacy of pomalidomide (CC-4047) in subjects with primary, post polycythemia vera, or post essential thrombocythemia myelofibrosis (PMF; post-PV MF, or post-ET MF)
Principal Investigator:Srdan Verstovsek
Treatment Agent:CC 4047; Prednisone
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if CC-4047 (now called
pomalidomide) and prednisone can help to control MMM. The safety of this
therapy will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:CC 4047
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:Celgene
Return Visit: Study visits will occur at the end of Cycles 1,2,3 and 6, then can be extended
to every 6 cycles if patient hasn't had any Grade 3-4 toxicity during the
previous 3 cycles.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults